Internal Medicine, Endocrinology, Diabetes, & Metabolism · Greenville, NC
NPI
1356699904
Since 2012
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
1006 Wh Smith Blvd., Physicians East - Endocrinology
Greenville, NC, 27834
Phone (252) 413-6683
Groups this clinician bills Medicare through
Medicare paid, 2024
$242K
10,138 services
Medicare patients, 2024
767
Average age 73
Drug cost, 2024
$4.3M
7,209 prescriptions
Company payments, 2025
$736
From 13 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mohammad R Azad was code J0897 (injection, denosumab, 1 mg), 4,080 times for 39 patients. In total Mohammad R Azad billed 10,138 services in 89 codes, and Medicare paid $242K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-07-21.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 4,080 | 39 | $20.38 | $83K |
| 99214 Office E&M - Established | Office | 729 | 435 | $88.46 | $64K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 454 | 335 | $12.12 | $5,501 |
| 83036 Blood Count | Office | 430 | 227 | $9.49 | $4,081 |
| 82962 Clinical Chemistry | Office | 353 | 218 | $3.20 | $1,129 |
| 36415 Venipuncture Blood Collection | Office | 317 | 262 | $8.65 | $2,742 |
| 95251 Test - Miscellaneous | Office | 255 | 125 | $25.58 | $6,523 |
| 77080 Standard X-ray | Office | 252 | 252 | $18.13 | $4,570 |
| 84443 Clinical Chemistry | Office | 206 | 172 | $16.40 | $3,378 |
| 84439 Clinical Chemistry | Office | 127 | 101 | $8.84 | $1,123 |
| 99204 Office E&M - New | Office | 120 | 120 | $117.42 | $14K |
| 96372 Injection Administration | Office | 107 | 48 | $9.62 | $1,030 |
| 76536 Ultrasound - Nonspecific | Office | 96 | 90 | $62.06 | $5,958 |
| 80053 Clinical Chemistry | Office | 93 | 90 | $10.35 | $963 |
| 99457 E&M - Miscellaneous | Office | 88 | 29 | $35.71 | $3,142 |
By year: 2022 $248K for 13,778 services; 2023 $263K for 14,473 services; 2024 $242K for 10,138 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 83036 Blood Count | 430 | 227 | $9.49 | $4,081 |
| 82962 Clinical Chemistry | 353 | 218 | $3.20 | $1,129 |
| 36415 Venipuncture Blood Collection | 317 | 262 | $8.65 | $2,742 |
| 84443 Clinical Chemistry | 206 | 172 | $16.40 | $3,378 |
| 84439 Clinical Chemistry | 127 | 101 | $8.84 | $1,123 |
| 80053 Clinical Chemistry | 93 | 90 | $10.35 | $963 |
| 83970 Clinical Chemistry | 73 | 68 | $40.01 | $2,920 |
| 82306 Clinical Chemistry | 66 | 64 | $29.01 | $1,915 |
| 82570 Clinical Chemistry | 56 | 56 | $5.08 | $284 |
| 82043 Clinical Chemistry | 55 | 55 | $5.66 | $311 |
Medicare prescription drug claims, 2024
In 2024, the drug Mohammad R Azad prescribed most often to Medicare patients was Ozempic (Semaglutide), with 800 prescriptions and refills. In total Mohammad R Azad wrote 7,209 Medicare prescriptions that cost $4.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ozempic Semaglutide | 800 | 1,133 | 150 | $1.1M |
| Levothyroxine Sodium Generic | 542 | 1,312 | 147 | $6,814 |
| Farxiga Dapagliflozin Propanediol | 382 | 540 | 73 | $294K |
| Soliqua 100-33 Insulin Glargine/Lixisenatide | 365 | 459 | 88 | $378K |
| Metformin Hcl Er Metformin Hcl | 332 | 775 | 102 | $3,513 |
| Mounjaro Tirzepatide | 242 | 288 | 48 | $302K |
| Jardiance Empagliflozin | 234 | 348 | 50 | $197K |
| Glipizide Er Glipizide | 210 | 481 | 75 | $2,354 |
| Novolog Flexpen Insulin Aspart | 166 | 259 | 59 | $39K |
| Metformin Hcl Generic | 160 | 409 | 45 | $1,141 |
| Tresiba Flextouch U-100 Insulin Degludec | 157 | 274 | 54 | $99K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 152 | 209 | 44 | $19K |
| Rybelsus Semaglutide | 150 | 176 | 47 | $164K |
| Synthroid Levothyroxine Sodium | 139 | 341 | 33 | $14K |
| Tresiba Flextouch U-200 Insulin Degludec | 133 | 209 | 30 | $148K |
Brand drugs: 4,575 claims; generic drugs: 2,173 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mohammad R Azad $736 ($736 in general payments such as food, travel and fees) from 13 companies. The largest payer was Sequel Med Tech, LLC with $222.
| Company | Payments | Amount |
|---|---|---|
| Sequel Med Tech, LLC | 3 | $222 |
| CeQur Corporation | 1 | $95.75 |
| Corcept Therapeutics CORT | 4 | $89.8 |
| Averitas Pharma Inc. | 2 | $65.08 |
| Beta Bionics, Inc. BBNX | 2 | $63.75 |
| Neurocrine BioSciences, Inc. NBIX | 2 | $61.42 |
| Novo Nordisk Inc NVO | 2 | $43.43 |
| Sanofi-Aventis U.S. LLC SNY | 1 | $17.32 |
| Amgen Inc. AMGN | 1 | $16.55 |
| Lilly USA, LLC LLY | 1 | $16.33 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.